今日の競争の激しいバイオテクノロジー分野では、知的財産権（IP）の保護が、創薬や開発におけるイノベーションと協力を促進する重要な柱となっています。明確なIP条件とロイヤリティフリーの提供により、製薬企業や研究機関は効率的かつ自由に抗体探索を進めることが可能となります。

In March 2024, Cyagen and Biointron officially signed off on their strategic partnership, forging an alliance in antibody drug development. This partnership aims to fully leverage the strengths of Cyagen's HUGO-Ab™ fully humanized mouse antibody discovery platform and Biointron&#

Biointron is proud to announce a strategic partnership with FatiAbGen, a leading biotechnology firm focused on antibody-based therapeutics. As the newly appointed Korean distributor for Biointron, FatiAbGen will be at the forefront of delivering Biointron’s products to the Korean market.